GO-8: Preliminary Results of a Phase I/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant

被引：31

作者：

Nathwani, Amit C. ^{[1
,2
,3
,4
]}

Tuddenham, Edward ^{[5
]}

Chowdary, Pratima ^{[6
]}

McIntosh, Jenny ^{[4
]}

Lee, Doyoung ^{[5
]}

Rosales, Cecilia ^{[5
]}

Phillips, Mark ^{[7
]}

Pie, Jun ^{[8
]}

Zhou Junfang ^{[9
]}

Meagher, Michael M. ^{[10
]}

Reiss, Ulrike ^{[11
]}

Davidoff, Andrew M. ^{[12
]}

Morton, Chris L. ^{[9
]}

Riddell, Anne ^{[2
,3
]}

机构：

[1] Freeline, Stevenage, Herts, England

[2] Royal Free NHS Fdn Trust, Katharine Dormandy Haemophilia Ctr, London, England

[3] Royal Free NHS Fdn Trust, Thrombosis Unit, London, England

[4] UCL, Canc Inst, Dept Haematol, London, England

[5] UCL Canc Inst, Dept Haematol, London, England

[6] Royal Free Hosp, KD Haemophilia & Thrombosis Ctr, London, England

[7] UCL, UCL Canc Inst, London, England

[8] KD Haemophilia & Thrombosis Ctr, London, England

[9] St Jude Childrens Res Hosp, Dept Surg, 332 N Lauderdale St, Memphis, TN 38105 USA

[10] St Jude Childrens Res Hosp, Childrens GMP LLC, 332 N Lauderdale St, Memphis, TN 38105 USA

[11] St Jude Childrens Rsch Hosp, Dept Surg, Memphis, TN USA

[12] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-118256

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

489

引用

页数：3

共 50 条

[21] Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial
Oraee-Yazdani, Saeed
Tavanaei, Roozbeh
Rostami, Fatemeh
Hajarizadeh, Atieh
Mehrabadi, Marzieh
Akhlaghpasand, Mohammadhosein
Tamaddon, Mona
Khannejad, Samin
Yazdani, Kaveh Oraii
Zali, Alireza
JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
[22] Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial
Saeed Oraee-Yazdani
Roozbeh Tavanaei
Fatemeh Rostami
Atieh Hajarizadeh
Marzieh Mehrabadi
Mohammadhosein Akhlaghpasand
Mona Tamaddon
Samin Khannejad
Kaveh Oraii Yazdani
Alireza Zali
Journal of Translational Medicine, 21
[23] Angiogenesis protein therapy with human fibroblast growth factor (fgf-1): results of a phase I open label, dose escalation study in subjects with CAD not eligible for PCI or CABG
Wagoner, Lynne E.
Merrill, Walter
Jacobs, Jack
Conway, Ginger
Boehmer, John
Thomas, Kenneth
Stegmann, Thomas
CIRCULATION, 2007, 116 (16) : 443 - 443
[24] Safety and preliminary efficacy of LYS-GM101 gene therapy in patients with GM1 gangliosidosis: Results of a phase I/II openlabel clinical trial
Ghosh, Arunabha
Heron, Benedicte
Donald, Aimee
Chang, Harriet
Furness, Laura
Movsesyan, Nina
Ravelli, Claudia
Jones, Simon
Wang, Raymond Y.
MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
[25] Preliminary results of a phase 1/2 trial of SPK-9001, a hyperactive FIX variant delievered by a novel capsid, demonstrate Consistent Factor IX Activity Levels at the lowest dose cohort
George, Lindsey
Sullivan, Spencer
Luk, Alvin
Anguela, Xavier
Teitel, Jerry
High, Katherine
HAEMOPHILIA, 2016, 22 : 33 - 33
[26] Preliminary Results of a Phase 1 Dose-Escalation Trial for Early-Stage Breast Cancer Using 5-Fraction Stereotactic Body Radiation Therapy for Partial-Breast Irradiation
Rahimi, Asal
Thomas, Kimberly
Spangler, Ann
Rao, Roshni
Leitch, Marilyn
Wooldridge, Rachel
Rivers, Aeisha
Seiler, Stephen
Albuquerque, Kevin
Stevenson, Stella
Goudreau, Sally
Garwood, Dan
Haley, Barbara
Euhus, David
Heinzerling, John
Ding, Chuxiong
Gao, Ang
Ahn, Chul
Timmerman, Robert
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 196 - +
[27] Preliminary results of a phase I trial using retroviral gene transfer of G156A MGMT to protect hematopoiesis during BG and BCNU therapy of advanced malignancies
Reese, J
Lingas, K
Ksenich, P
Sweeney, C
Koc, O
Gerson, S
MOLECULAR THERAPY, 2004, 9 : S385 - S385
[28] RESULTS FROM A PHASE I/II CLINICAL TRIAL ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR GENE THERAPY IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION
Lai, Chooi-May
Magno, Aaron
Pierce, Cora
Samulski, Richard J.
Chalberg, Thomas W.
Blumenkranz, Mark S.
Constable, Ian J.
Rakoczy, Elizabeth P.
JOURNAL OF GENE MEDICINE, 2013, 15 (8-9): : 319 - 319
[29] Gene Therapy for Beta Thalassemia: Preliminary Results from the PHASE I/II Tiget-Bthal Trial of Autologous Hematopoietic Stem Cells Genetically Modified with GLOBE Lentiviral Vector
Marktel, Sarah
Cicalese, Maria Pia
Giglio, Fabio
Scaramuzza, Samantha
Calbi, Valeria
Casiraghi, Miriam
Ciotti, Francesca
Lidonnici, Maria Rosa
Rossi, Claudia
Masera, Nicoletta
D'Angelo, Emanuela
Mirra, Nadia
Origa, Raffaella
Tartaglione, Immacolata
Mandelli, Giacomo
Milani, Raffaella
Gattillo, Salvatore
Coppola, Milena
Viarengo, Gianluca
Santoleri, Luca
Calabria, Andrea
Perrotta, Silverio
Montini, Eugenio
Graziadei, Giovanna
Naldini, Luigi
Cappellini, Maria Domenica
Ciceri, Fabio
Aiuti, Alessandro
Ferrari, Giuliana
BLOOD, 2017, 130
[30] Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER plus /human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial
Hamilton, E. P.
Han, H.
Schott, A.
Tan, A.
Nanda, R.
Juric, D.
Hunter, N.
Munster, P.
Fang, B.
Zahrah, G.
Ranciato, J.
Gedrich, R.
Zhi, E.
Zhang, Y.
Tan, W.
Mather, C.
Perkins, J.
Anderson, S.
Hurvitz, S. A.
ANNALS OF ONCOLOGY, 2023, 34 : S344 - S344

← 1 2 3 4 5 →